Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic Dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aquinox Pharma (AQXP) Reports Negative KINSHIP Trial Data; Cowen Maintains Outperform
November 3, 2015 2:22 PM ESTCowen maintained an Outperform rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and cut the price target to $23.00 (from $24.00), following negative KINSHIP trial data. The KINSHIP trial demonstrated AQX-1125 to be well tolerated and adverse events were consistent with prior clinical trials. No serious adverse... More
Needham & Company Keeps Aquinox Pharma (AQXP) at 'Buy'; Failure of AQX-1125 in Atopic Dermatitis Won't Impact Model
November 3, 2015 9:48 AM ESTNeedham & Company affirms Aquinox Pharma (Nasdaq: AQXP) with a Buy rating and $25 price target after the company... More
Aquinox Pharma's (AQXP) Phase 2 KINSHIP Trial With AQX-1125 Fails to Demonstrate Efficacy
November 3, 2015 6:36 AM ESTAquinox Pharmaceuticals, Inc. (Aquinox) (Nasdaq: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today its Phase 2 KINSHIP clinical trial failed to demonstrate efficacy in patients with mild to moderate atopic dermatitis.
"We believe that... More
